Pharmacy & Therapeutics - April 2008 - (Page 243) CONTINUING EDUCATION CREDIT 9. Raphael RI, Vichinsky EP. Pathophysiology and treatment of sickle cell disease. Clin Adv Hematol Oncol 2005;3:492–505. 10. Iannone R, Ohene-Frempong K, Fuchs EJ, et al. Bone marrow transplantation for sickle cell anemia: Progress and prospects. Pediatr Blood Cancer 2005;44:436–440. 11. Bunn HF. Pathogenesis and treatment of sickle cell disease. N Engl J Med 1997;337:762–769. 12. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med 1995;332:1317–1322. 13. Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on morbidity and mortality in adult sickle cell anemia: Risks and benefits up to 9 years of treatment. JAMA 2003;289:1645–1651. 14. Ferster A, Vermylen C, Cornu G, et al. Hydroxyurea for treatment of severe sickle cell anemia: A pediatric clinical trial. Blood 1996;88(6):1960–1964. 15. Kinner TR, Helms RW, O’Branski EE, et al., Pediatric Hydroxyurea Group. Safety of hydroxyurea in children with sickle cell anemia: Results of the HUG–KIDS study, a phase I/II trial. Blood 1999;94(5):1550–1554. 16. Zimmerman SA, Schultz WH, Davis JS, et al. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood 2004;103(6):2039–2045. 17. Marlowe KF, Chicella MF. Treatment of sickle cell pain. Pharmacotherapy 2002;22(4):484–491. 18. Gonzalez ER, Bahal N, Hansen LA, et al. Intermittent injection vs. patient-controlled analgesia for sickle cell crisis pain: Comparison in patients in the emergency department. Arch Intern Med 1991;151(7):1373–1378. 19. Okomo U, Meremikwu MM. Fluid replacement therapy for acute episodes of pain in people with sickle cell disease (Cochrane Review). In: The Cochrane Library. Issue 2, 2007. Article No. CD005406. 20. Steinberg MH. Management of sickle cell disease. N Engl J Med 1999;340:1021–1029. 21. Falletta JM, Woods GM, Verter JI, et al. Discontinuing penicillin prophylaxis in children with sickle cell anemia. J Pediatr 1995; 127:685–690. 22. The Management of Sickle Cell Disease, 4th ed. revised, June 2002. National Institutes of Health/National Heart, Lung, and Blood Institute, Division of Blood Diseases and Resources, NIH Pub No. 02-2117. 23. Gatson MH, Verter JI, Woods G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia: A randomized trial. N Engl J Med 1986;314:1593–1599. 24. What is sickle cell anemia? National Heart, Lung, and Blood Institute (NHLBI). Available at: www.nhlbi.nih.gov/health/dci/ Diseases/Sca/SCA_WhatIs.html. Accessed August 10, 2007. 25. Pai VB, Nahata MC. Duration of penicillin prophylaxis in sickle cell anemia: Issues and controversies. Pharmacotherapy 2000; 20(1):110–117. 26. Centers for Disease Control and Prevention (DCDC). Sickle cell disease: Five tips to help prevent infection. Available at: www. cdc.gov/ncbddd/sicklecell/tips_prevent.htm. Accessed October 16, 2007. 27. Adams RJ, McKie VC, Hsu L et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med 1998;339:5–11. 28. The Optimizing Primary Stroke Prevention in Sickle Cell Anemia (STOP 2) Trial Investigators. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med 2005;353:2769–2778. 29. Zimmerman SA, Schultz WH, Burgett S, et al. Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia. Blood 2007;110:1043–1047. 30. Vichinsky E, Onyekwere O, Porter J, et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol 2007;136(3):501–508. 31. Lerner NB. Aspirin prophylaxis in sickle cell disease. Trial No. NCT00178464. Available at: http://clinicaltrials.gov/ct/show/ NCT00178464?order=1. Accessed September 5, 2007. 32. Stuart MJ, Nagel RL. Sickle cell disease. Lancet 2004;364(9442): 1343–1360. 33. Rabb LM, Grandison Y, Mason K, et al. A trial of folate supplementation in children with homozygous sickle cell disease. Br J Haematol 1983;54:589–594. 34. Rodriguez-Cortez HM, Griener JC, Hyland K, et al. Plasma homocysteine levels and folate status in children with sickle cell anemia. J Pediatr Hematol Oncol 1999;21:219–223. 35. Nelson SC, Adade BB, McDonough EA, et al. High prevalence of pulmonary hypertension in children with sickle cell disease. J Pediatr Hematol Oncol 2007;29:334–337. 36. Castro O, Hoque M, Brown MD. Pulmonary hypertension in sickle cell disease: Cardiac catheterization results and survival. Blood 2003;101:1257–1261. 37. Machado RF, Martyr S, Kato GJ et al. Sildenafil therapy in patients with sickle-cell disease and pulmonary hypertension. Br J Haematol 2005;130:445–453. 38. Adeyoju AB, Olujohunbge ABK, Morris J, et al. Priapism in sicklecell disease: Incidence, risk factors and complications. An international multicentre study. BJU Int 2002;90(9):898–902. 39. Fowler JE, Koshy M, Strub M, et al. Priapism associated with the sickle cell hemoglobinopathies: Prevalence, natural history and sequelae. J Urol 1991;145(1):65–68. 40. Pryor J, Akkus E, Alter G, et al. Priapism. J Sex Med 2004;1(1): 116–120. 41. Iyamu EW, Turner EA, Asakura T. In vitro effects of niprisan (Nix0699): A naturally occurring, potent antisickling agent. Br J Haematol 2002;118(1):337–343. 42. Wambebe C, Khamofu H, Momoh JA, et al. Double-blind, placebocontrolled, randomized cross-over clinical trial of niprisan in patients with sickle cell disorder. Phytomedicine 2001;8(4):252– 261. 43. Stuart MJ, Nagel RL. Sickle-cell disease. Lancet 2004;364:1343– 1360. 44. Christensen D. Nitric oxide may help treat sickle cell anemia. Science News 2000;157(5):78–81. 45. Head CA, Brugnara C, Martinez-Ruiz R, et al. Low concentrations of nitric oxide increase oxygen affinity of sickle erythrocytes in vitro and in vivo. J Clin Invest 1997;100(5):1193–1198. 46. Waugh WH, Daeschner CW, Files BA, et al. Evidence that L-arginine is a key amino acid in sickle cell anemia: A preliminary report. Nutr Res 1999;19(4):501–518. 47. Morris CR, Morris SM, Hagar W, et al. Arginine therapy: A new treatment for pulmonary hypertension in sickle cell disease? Am J Respir Crit Care Med 2003;168:63–69. 48. Williams R, Olivi S, Li CS, et al. Oral glutamine supplementation decreases resting energy expenditure in children and adolescents with sickle cell anemia. J Pediatr Hematol Oncol 2004;26(10): 619–625. 49. Niihara Y, Zerez CR, Akiyama DS, et al. Increased red cell glutamine availability in sickle cell anemia: Demonstration of increased active transport, affinity, and increased glutamate level in intact red cells. J Lab Clin Med 1997;130(1):83–90. 50. Niihara Y, Zerez CR, Akiyama DS, et al. Oral L-glutamine therapy for sickle cell anemia: I. Subjective clinical improvement and favorable change in red cell NAD redox potential. Am J Hematol 1998;58:117–121. 51. De Franceschi L, Bachir D, Galacteros F, et al. Oral magnesium supplements reduce erythrocyte dehydration in patients with sickle cell disease. J Clin Invest 1997;100(7):1847–1852. I Conflict of Interest (COI) Statement The authors have no relationships to disclose. The article contains a discussion of off-label use. The content of this article has been reviewed under Jefferson’s COI policy. Vol. 33 No. 4 • April 2008 • P&T® 243 http://clinicaltrials.gov/ct/show/NCT00178464?order=1 http://www.nhlbi.nih.gov/health/dci/Diseases/Sca/SCA_WhatIs.html http://www.nhlbi.nih.gov/health/dci/Diseases/Sca/SCA_WhatIs.html http://www.cdc.gov/ncbddd/sicklecell/tips_prevent.htm http://www.cdc.gov/ncbddd/sicklecell/tips_prevent.htm http://clinicaltrials.gov/ct/show/NCT00178464?order=1
For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.